CVS Health Corp. logo CVS - CVS Health Corp.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
2
BUY 33
HOLD 6
SELL 0
STRONG
SELL
0
| PRICE TARGET: $110.47 DETAILS
HIGH: $126.00
LOW: $92.00
MEDIAN: $111.00
CONSENSUS: $110.47
UPSIDE: 18.66%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Strong
Trading 43.8% above fair value
Current Price $93.10
Bear Case $51.79 44.4% downside ($51.79 - $93.10) / $93.10 = -44.4% $4.68 × 11x P/E
Fair Value $64.74 30.5% downside ($64.74 - $93.10) / $93.10 = -30.5% $4.68 × 14x P/E
Bull Case $77.69 16.6% downside ($77.69 - $93.10) / $93.10 = -16.6% $4.68 × 17x P/E

Adjust Assumptions

13.8x
4.68$

Key Value Driver

Normalized P/E multiple (14x base case)

Implied Market Multiple 19.9x

Plain-Language Summary

Applying a 14x P/E to adjusted EPS of $4.68, the base-case value is $64.74 per share. DDM cross-check: $76.03.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (41 analysts) $110.47
Analyst Range $92.00 – $126.00
Divergence from AlphaVal 41%

Warnings

The company's reported profits differ from official accounting profits by 237%. Check what costs are being left out of the adjusted number.
The company pays out 191% of its profits as dividends. That leaves little cushion — the dividend could be cut if business slows down.
Wall Street's average price target is $110.47 (from 41 analysts). Our estimate is 41% below the consensus -- consider that gap carefully.

Key Risks

  • Growth DCF inappropriate — terminal value assumptions dominate
  • EV/EBITDA misleading for regulated businesses where capex is mandated
  • Regulatory risk is a fat tail not visible in normal multiples